Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression
One of the major limitations to current gene therapy is the low-level and transient vector gene expression due to poorly defined mechanisms, possibly including promoter attenuation or extinction. Because the application of gene therapy vectors in vivo induces cytokine production through specific or...
Gespeichert in:
| Veröffentlicht in: | Human gene therapy Jg. 8; H. 17; S. 2019 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
20.11.1997
|
| Schlagworte: | |
| ISSN: | 1043-0342 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | One of the major limitations to current gene therapy is the low-level and transient vector gene expression due to poorly defined mechanisms, possibly including promoter attenuation or extinction. Because the application of gene therapy vectors in vivo induces cytokine production through specific or nonspecific immune responses, we hypothesized that cytokine-mediated signals may alter vector gene expression. Our data indicate that the cytokines interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) inhibit transgene expression from certain widely used viral promoters/enhancers (cytomegalovirus, Rous sarcoma virus, simian virus 40, Moloney murine leukemia virus long terminal repeat) delivered by adenoviral, retroviral or plasmid vectors in vitro. A constitutive cellular promoter (beta-actin) is less sensitive to these cytokine effects. Inhibition is at the mRNA level and cytokines do not cause vector DNA degradation, inhibit total cellular protein synthesis, or kill infected/transfected cells. Administration of neutralizing anti-IFN-gamma monoclonal antibody results in enhanced transgene expression in vivo. Thus, standard gene therapy vectors in current use may be improved by altering cytokine-responsive regulatory elements. Determination of the mechanisms involved in cytokine-regulated vector gene expression may improve the understanding of the cellular disposition of vectors for gene transfer and gene therapy. |
|---|---|
| AbstractList | One of the major limitations to current gene therapy is the low-level and transient vector gene expression due to poorly defined mechanisms, possibly including promoter attenuation or extinction. Because the application of gene therapy vectors in vivo induces cytokine production through specific or nonspecific immune responses, we hypothesized that cytokine-mediated signals may alter vector gene expression. Our data indicate that the cytokines interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) inhibit transgene expression from certain widely used viral promoters/enhancers (cytomegalovirus, Rous sarcoma virus, simian virus 40, Moloney murine leukemia virus long terminal repeat) delivered by adenoviral, retroviral or plasmid vectors in vitro. A constitutive cellular promoter (beta-actin) is less sensitive to these cytokine effects. Inhibition is at the mRNA level and cytokines do not cause vector DNA degradation, inhibit total cellular protein synthesis, or kill infected/transfected cells. Administration of neutralizing anti-IFN-gamma monoclonal antibody results in enhanced transgene expression in vivo. Thus, standard gene therapy vectors in current use may be improved by altering cytokine-responsive regulatory elements. Determination of the mechanisms involved in cytokine-regulated vector gene expression may improve the understanding of the cellular disposition of vectors for gene transfer and gene therapy.One of the major limitations to current gene therapy is the low-level and transient vector gene expression due to poorly defined mechanisms, possibly including promoter attenuation or extinction. Because the application of gene therapy vectors in vivo induces cytokine production through specific or nonspecific immune responses, we hypothesized that cytokine-mediated signals may alter vector gene expression. Our data indicate that the cytokines interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) inhibit transgene expression from certain widely used viral promoters/enhancers (cytomegalovirus, Rous sarcoma virus, simian virus 40, Moloney murine leukemia virus long terminal repeat) delivered by adenoviral, retroviral or plasmid vectors in vitro. A constitutive cellular promoter (beta-actin) is less sensitive to these cytokine effects. Inhibition is at the mRNA level and cytokines do not cause vector DNA degradation, inhibit total cellular protein synthesis, or kill infected/transfected cells. Administration of neutralizing anti-IFN-gamma monoclonal antibody results in enhanced transgene expression in vivo. Thus, standard gene therapy vectors in current use may be improved by altering cytokine-responsive regulatory elements. Determination of the mechanisms involved in cytokine-regulated vector gene expression may improve the understanding of the cellular disposition of vectors for gene transfer and gene therapy. One of the major limitations to current gene therapy is the low-level and transient vector gene expression due to poorly defined mechanisms, possibly including promoter attenuation or extinction. Because the application of gene therapy vectors in vivo induces cytokine production through specific or nonspecific immune responses, we hypothesized that cytokine-mediated signals may alter vector gene expression. Our data indicate that the cytokines interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) inhibit transgene expression from certain widely used viral promoters/enhancers (cytomegalovirus, Rous sarcoma virus, simian virus 40, Moloney murine leukemia virus long terminal repeat) delivered by adenoviral, retroviral or plasmid vectors in vitro. A constitutive cellular promoter (beta-actin) is less sensitive to these cytokine effects. Inhibition is at the mRNA level and cytokines do not cause vector DNA degradation, inhibit total cellular protein synthesis, or kill infected/transfected cells. Administration of neutralizing anti-IFN-gamma monoclonal antibody results in enhanced transgene expression in vivo. Thus, standard gene therapy vectors in current use may be improved by altering cytokine-responsive regulatory elements. Determination of the mechanisms involved in cytokine-regulated vector gene expression may improve the understanding of the cellular disposition of vectors for gene transfer and gene therapy. |
| Author | Qin, L Imperiale, M J Pahud, D R Bromberg, J S Ding, Y Chang, E |
| Author_xml | – sequence: 1 givenname: L surname: Qin fullname: Qin, L organization: Department of Surgery, University of Michigan, Ann Arbor 48109-0331, USA – sequence: 2 givenname: Y surname: Ding fullname: Ding, Y – sequence: 3 givenname: D R surname: Pahud fullname: Pahud, D R – sequence: 4 givenname: E surname: Chang fullname: Chang, E – sequence: 5 givenname: M J surname: Imperiale fullname: Imperiale, M J – sequence: 6 givenname: J S surname: Bromberg fullname: Bromberg, J S |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/9414251$$D View this record in MEDLINE/PubMed |
| BookMark | eNotkDtPwzAYRT0UlbbwB5CQPLGl-JGHzYYqXlIlGLpHjv2lCYrtYDsS_fcE6HSlq3PPcNdo4bwDhG4o2VIi5H032S2VstqKLa0yRqhcoBUlOc8Iz9klWsf4SQjlRVkt0VLmNGcFXaH4Ebz1CQJWKYGbVOq9w73DR3CAUwdBjaeHuZiRFoJ32VFZq7ByBqfJ-oAd6OBjH3GrdPIhU8PYqXnQ9U2fcArKxT8XfI8BYpz1V-iiVUOE63Nu0OH56bB7zfbvL2-7x32mc8pTRgUTOW0azgqjuSig4pox0rStqAwHoQtDGCkq1UihNBBWSk2NNk1lSl1ytkF3_9ox-K8JYqptHzUMg3Lgp1hXMpe0kL_g7RmcGgumHkNvVTjV55PYD0JtbOs |
| CitedBy_id | crossref_primary_10_1016_j_jconrel_2013_08_025 crossref_primary_10_1038_mt_2010_13 crossref_primary_10_1038_s41598_021_99263_3 crossref_primary_10_1046_j_1365_2249_2003_02124_x crossref_primary_10_1038_sj_gt_3300851 crossref_primary_10_1038_sj_gt_3302231 crossref_primary_10_1128_JVI_75_10_4540_4550_2001 crossref_primary_10_1016_j_biomaterials_2016_03_029 crossref_primary_10_1208_aapsj070109 crossref_primary_10_1016_j_trim_2007_05_004 crossref_primary_10_1002_jgm_384 crossref_primary_10_1038_sj_gt_3300989 crossref_primary_10_1038_sj_gt_3301958 crossref_primary_10_1002_jps_21302 crossref_primary_10_1016_j_biomaterials_2008_09_013 crossref_primary_10_1016_j_bbagen_2005_06_016 crossref_primary_10_1089_hum_2005_16_126 crossref_primary_10_1128_JVI_00297_09 crossref_primary_10_1016_S0168_0102_99_00055_3 crossref_primary_10_1128_JVI_72_6_4882_4892_1998 crossref_primary_10_1016_S0378_5173_02_00194_1 crossref_primary_10_3390_jpm10040258 crossref_primary_10_1128_JVI_80_7_3293_3300_2006 crossref_primary_10_1007_s13238_011_1126_y crossref_primary_10_1002__SICI_1521_2254_200001_02_2_1_41__AID_JGM79_3_0_CO_2_P crossref_primary_10_1002__SICI_1096_9896_199902_187_3_365__AID_PATH237_3_0_CO_2_Z crossref_primary_10_1038_sj_gt_3302815 crossref_primary_10_1371_journal_pone_0244386 crossref_primary_10_1038_sj_gt_3302136 crossref_primary_10_1016_j_lfs_2010_08_012 crossref_primary_10_1093_hmg_ddt372 crossref_primary_10_1006_mthe_2002_0689 crossref_primary_10_1002__SICI_1097_4547_19990115_55_2_147__AID_JNR2_3_0_CO_2_8 crossref_primary_10_1038_sj_mt_6300024 crossref_primary_10_1016_j_ejps_2009_03_013 crossref_primary_10_1186_1297_9716_45_21 crossref_primary_10_1016_S0022_1759_99_00104_0 crossref_primary_10_1016_S1040_8428_00_00113_X crossref_primary_10_1111_j_1440_1711_2005_01379_x crossref_primary_10_1128_JVI_01571_06 crossref_primary_10_1038_sj_gt_3302700 crossref_primary_10_1038_gt_2011_35 crossref_primary_10_1089_dna_2006_25_659 crossref_primary_10_4049_jimmunol_164_11_5739 crossref_primary_10_1016_S0925_4439_00_00084_3 crossref_primary_10_4049_jimmunol_166_4_2385 crossref_primary_10_1038_sj_gt_3301298 crossref_primary_10_1038_sj_gt_3301297 crossref_primary_10_1038_sj_gt_3301296 crossref_primary_10_1089_hum_1998_9_10_1395 crossref_primary_10_1038_sj_gt_3302031 crossref_primary_10_1016_j_jconrel_2025_01_017 crossref_primary_10_1016_S0264_410X_02_00081_6 crossref_primary_10_1002_med_20009 crossref_primary_10_1089_hum_2015_075 crossref_primary_10_1006_cyto_2000_0689 crossref_primary_10_1002_jgm_1317 crossref_primary_10_1128_JVI_72_11_9267_9277_1998 crossref_primary_10_1016_j_biomaterials_2015_04_024 crossref_primary_10_1016_j_virol_2010_12_053 crossref_primary_10_1038_sj_gt_3300933 crossref_primary_10_1517_14712598_8_10_1507 crossref_primary_10_1007_BF03402189 crossref_primary_10_1016_j_plipres_2022_101182 crossref_primary_10_1208_s12248_012_9423_9 crossref_primary_10_1034_j_1600_6143_2003_00076_x crossref_primary_10_1165_rcmb_2007_0458OC crossref_primary_10_1038_sj_gt_3301222 crossref_primary_10_1016_j_ijpharm_2007_06_012 crossref_primary_10_1080_08830180600785827 crossref_primary_10_1111_j_1365_2567_2006_02451_x crossref_primary_10_4137_BMI_S20063 crossref_primary_10_1006_viro_2002_1700 crossref_primary_10_1016_j_ijpharm_2005_08_020 crossref_primary_10_1038_gt_2017_82 crossref_primary_10_1038_sj_mt_6300002 crossref_primary_10_1146_annurev_biophys_29_1_27 crossref_primary_10_1227_00006123_199907000_00029 crossref_primary_10_1016_j_ymthe_2004_01_007 crossref_primary_10_1002_jgm_1208 crossref_primary_10_1016_j_virol_2005_08_040 crossref_primary_10_1006_exmp_2001_2391 crossref_primary_10_1089_10430349950017202 crossref_primary_10_1038_10567 crossref_primary_10_1007_s11906_000_0065_4 crossref_primary_10_1016_S0006_291X_02_00210_3 crossref_primary_10_1038_sj_gt_3301482 crossref_primary_10_1128_CVI_05180_11 crossref_primary_10_1006_mthe_2002_0598 crossref_primary_10_1016_S1470_2045_03_01139_2 crossref_primary_10_1097_00006123_199907000_00029 crossref_primary_10_1006_bbrc_2000_4029 crossref_primary_10_1016_S1525_0016_03_00008_X crossref_primary_10_1038_mt_2010_1 crossref_primary_10_1002_jgm_232 crossref_primary_10_1002_jgm_352 crossref_primary_10_1007_s00253_024_13003_x crossref_primary_10_1517_14712598_2013_735656 crossref_primary_10_1089_10430340050032384 crossref_primary_10_1182_blood_2001_11_0067 crossref_primary_10_1002_jps_20879 crossref_primary_10_1006_exer_1999_0731 crossref_primary_10_1002_jgm_2992 crossref_primary_10_1016_j_biopha_2008_02_006 crossref_primary_10_1016_j_biomaterials_2021_120966 crossref_primary_10_1016_S1359_6446_00_01633_0 crossref_primary_10_1089_hum_2004_15_1022 crossref_primary_10_1006_mthe_2000_0197 crossref_primary_10_1002_jgm_805 crossref_primary_10_1080_01926230252929864 crossref_primary_10_1002_bit_27686 crossref_primary_10_1002_jgm_922 crossref_primary_10_1097_WNR_0b013e3283088e3d crossref_primary_10_1038_sj_gt_3301373 crossref_primary_10_1211_0022357021778817 crossref_primary_10_1023_A_1020989709019 crossref_primary_10_1046_j_1600_6135_2003_00263_x crossref_primary_10_1089_hum_2004_15_1255 crossref_primary_10_1016_S0264_410X_99_00418_1 crossref_primary_10_1038_gt_2010_173 crossref_primary_10_1016_S1525_0016_03_00059_5 crossref_primary_10_1089_10430349950017518 crossref_primary_10_1016_S0168_8227_01_00220_0 crossref_primary_10_1038_sj_gt_3302518 crossref_primary_10_2119_molmed_2011_00404 crossref_primary_10_1038_sj_gt_3301784 crossref_primary_10_1097_00007890_200001150_00021 crossref_primary_10_1038_cgt_2010_43 crossref_primary_10_1016_j_plasmid_2021_102556 crossref_primary_10_1128_JVI_76_11_5692_5700_2002 crossref_primary_10_1002_jgm_1127 crossref_primary_10_1002_jgm_789 crossref_primary_10_1006_mthe_2001_0412 crossref_primary_10_1002_bit_21882 crossref_primary_10_1038_sj_gt_3302885 crossref_primary_10_1186_1479_5876_12_25 crossref_primary_10_1016_j_jconrel_2018_04_022 crossref_primary_10_1016_S1461_5347_98_00054_6 crossref_primary_10_1089_hum_2016_134 crossref_primary_10_1016_S0966_3274_02_00023_0 crossref_primary_10_1016_j_addr_2007_03_009 crossref_primary_10_2217_14796678_4_2_135 crossref_primary_10_1038_cgt_2009_45 crossref_primary_10_1038_gt_2008_4 crossref_primary_10_1089_hum_2005_16_881 crossref_primary_10_1189_jlb_0204089 crossref_primary_10_1016_S1016_8478_23_13740_X crossref_primary_10_1517_13543784_9_7_1523 crossref_primary_10_1016_S1525_0016_02_00032_1 crossref_primary_10_1038_gt_2008_109 crossref_primary_10_1038_sj_gt_3301561 crossref_primary_10_1038_sj_gt_3303073 crossref_primary_10_3171_spi_2002_96_2_0212 crossref_primary_10_1016_j_gene_2013_09_075 crossref_primary_10_1016_S0006_291X_02_02648_7 crossref_primary_10_1002_jgm_201 crossref_primary_10_1089_10430340252809810 crossref_primary_10_1111_j_1600_6143_2005_01042_x crossref_primary_10_1097_00007890_200011150_00006 crossref_primary_10_1002_ctm2_194 crossref_primary_10_1016_j_ymthe_2005_04_008 crossref_primary_10_1089_10430349950019011 crossref_primary_10_1097_00005344_200202000_00008 crossref_primary_10_1089_10799900050044778 crossref_primary_10_1155_2010_864029 crossref_primary_10_1089_hum_2019_336 crossref_primary_10_1111_j_1365_2249_2003_02363_x crossref_primary_10_1016_j_virol_2011_05_018 crossref_primary_10_1117_1_3253325 crossref_primary_10_1186_1479_0556_1_2 crossref_primary_10_1016_j_virol_2004_04_032 crossref_primary_10_1161_CIRCULATIONAHA_105_001370 crossref_primary_10_1111_j_1742_4658_2010_07769_x crossref_primary_10_1002_jps_20816 crossref_primary_10_1089_hum_2004_15_ft_2 crossref_primary_10_1016_j_healun_2006_11_604 crossref_primary_10_1006_cyto_2000_0839 crossref_primary_10_1016_S1525_0016_03_00211_9 crossref_primary_10_1073_pnas_96_11_6417 crossref_primary_10_1111_j_1574_695X_2000_tb01448_x crossref_primary_10_1016_j_addr_2009_04_011 crossref_primary_10_1002_adhm_201300629 crossref_primary_10_1089_10430349950016636 crossref_primary_10_1073_pnas_2436478100 crossref_primary_10_3748_wjg_v10_i4_567 crossref_primary_10_1111_j_1365_2567_2004_01814_x crossref_primary_10_3390_cells10040860 crossref_primary_10_1038_sj_cgt_7700617 crossref_primary_10_1016_j_jconrel_2007_10_014 crossref_primary_10_1089_153685903322328929 crossref_primary_10_1002_jgm_759 crossref_primary_10_1002_jgm_516 crossref_primary_10_1006_taap_2002_9372 crossref_primary_10_1089_152581699319948 crossref_primary_10_1016_S1040_8428_98_00043_2 crossref_primary_10_1203_00006450_200008000_00011 crossref_primary_10_1002_jgm_1493 crossref_primary_10_1128_AAC_45_4_1201_1209_2001 crossref_primary_10_1038_sj_gt_3302182 crossref_primary_10_1155_2015_346134 crossref_primary_10_1002_1531_8249_200007_48_1_27__AID_ANA6_3_0_CO_2_6 crossref_primary_10_1016_S1525_0016_03_00004_2 crossref_primary_10_4142_jvs_2006_7_4_361 crossref_primary_10_1155_2010_284840 crossref_primary_10_1006_mthe_2001_0435 crossref_primary_10_1038_sj_gt_3302626 crossref_primary_10_1002_jgm_1026 crossref_primary_10_1016_j_jss_2008_02_016 crossref_primary_10_1016_j_jconrel_2016_12_029 crossref_primary_10_1016_j_virol_2004_03_027 crossref_primary_10_1006_mthe_2001_0318 crossref_primary_10_1006_exnr_1998_6803 crossref_primary_10_1006_mthe_2000_0105 crossref_primary_10_1016_S0003_4975_01_03574_3 crossref_primary_10_1016_S0041_1345_98_01816_8 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1089/hum.1997.8.17-2019 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Biology |
| ExternalDocumentID | 9414251 |
| Genre | Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S Journal Article |
| GrantInformation_xml | – fundername: NIAMS NIH HHS grantid: P60-AR20557 – fundername: NIGMS NIH HHS grantid: R01 GM34902 |
| GroupedDBID | --- .55 .GJ 0R~ 34G 39C 4.4 53G 5GY 5RE ABBKN ABJNI ACGFO ACGFS ACIWK ACPRK ADBBV AENEX AFRAH ALMA_UNASSIGNED_HOLDINGS BNQNF CAG CGR COF CS3 CUY CVF DU5 EBS ECM EIF EJD F5P IH2 IHR L7B MV1 NPM O9- P2P RIG RML RMSOB X7M Y6R ZXP 7X8 SCNPE |
| ID | FETCH-LOGICAL-c413t-182841bb325dc385e73c220bff87d3e8c5d02057ab98ace0269c1dcdb7d6c632 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 265 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=10.1089_hum.1997.8.17-2019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1043-0342 |
| IngestDate | Fri Sep 05 09:18:34 EDT 2025 Thu Jan 02 21:46:12 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 17 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c413t-182841bb325dc385e73c220bff87d3e8c5d02057ab98ace0269c1dcdb7d6c632 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://deepblue.lib.umich.edu/bitstream/2027.42/63157/1/hum.1997.8.17-2019.pdf |
| PMID | 9414251 |
| PQID | 79491593 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_79491593 pubmed_primary_9414251 |
| PublicationCentury | 1900 |
| PublicationDate | 1997-11-20 |
| PublicationDateYYYYMMDD | 1997-11-20 |
| PublicationDate_xml | – month: 11 year: 1997 text: 1997-11-20 day: 20 |
| PublicationDecade | 1990 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Human gene therapy |
| PublicationTitleAlternate | Hum Gene Ther |
| PublicationYear | 1997 |
| References | 9414249 - Hum Gene Ther. 1997 Nov 20;8(17):2009-10 |
| References_xml | – reference: 9414249 - Hum Gene Ther. 1997 Nov 20;8(17):2009-10 |
| SSID | ssj0013567 |
| Score | 2.049225 |
| Snippet | One of the major limitations to current gene therapy is the low-level and transient vector gene expression due to poorly defined mechanisms, possibly including... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2019 |
| SubjectTerms | Adenoviruses, Human - genetics Animals Antibodies, Monoclonal - immunology Avian Sarcoma Viruses - genetics Cell Line Cytomegalovirus - genetics DNA, Viral - drug effects Drug Synergism Gene Expression Regulation - drug effects Genes, Reporter Genetic Therapy Genetic Vectors - drug effects Genetic Vectors - immunology Humans Interferon-gamma - immunology Interferon-gamma - pharmacology Lac Operon Mice Mice, Inbred C57BL Moloney murine leukemia virus - genetics Plasmids Promoter Regions, Genetic - drug effects Promoter Regions, Genetic - immunology RNA, Messenger Simian virus 40 - genetics Transformation, Genetic Transgenes - drug effects Tumor Necrosis Factor-alpha - immunology Tumor Necrosis Factor-alpha - pharmacology |
| Title | Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/9414251 https://www.proquest.com/docview/79491593 |
| Volume | 8 |
| WOSCitedRecordID | wos10.1089_hum.1997.8.17-2019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwED4BBcTCG_HGA6sh79gICSEEYqHqwNCtcvyADHVKmiL67zk7qcSCGFiy2Yp8X-6R830fwKXEIkGEiaGZyDRNEBNUqETRWLEgkSySmRJebCLv99lwyAdLcLuYhXHXKhc-0TtqVUn3j_waccMx9MZ3kw_qNKNcb7UT0FiGXoyJjMN0PvzRQ0i9fmzo-suO6K4bmQkYv36fjd2YXn7FrtBJR55n57cE0weap63_veI2bHYJJrlvEbEDS9ruwlorOTnfhfWXrpm-B9OBv4qna-I4Nm3L-U1KSxBTmrSDWfMb4gglaqPrytI3MR4LIqwizWxc1cRqF2TLKWlVe6gf3MUF72VRNqRxYdDvpb-667Z2H16fHl8fnmmnwUAlhreGYvnBkrAo4ihVMmapzmMZRUFhDMtVrJlMFSacaS4KzoTUWNFxGSqpilxlMoujA1ixldWHQDBz4yaSQWAMGkOm3GCmiTjBHbKA5_IILhanOkKIu76FsLqaTUeLcz2Cg9Ywo0nLxDHiSYg-Jzz-c-kJbHje2TBEa59Cz-C3rc9gVX425bQ-98DBZ3_w8g33mM_M |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Promoter+attenuation+in+gene+therapy%3A+interferon-gamma+and+tumor+necrosis+factor-alpha+inhibit+transgene+expression&rft.jtitle=Human+gene+therapy&rft.au=Qin%2C+L&rft.au=Ding%2C+Y&rft.au=Pahud%2C+D+R&rft.au=Chang%2C+E&rft.date=1997-11-20&rft.issn=1043-0342&rft.volume=8&rft.issue=17&rft.spage=2019&rft_id=info:doi/10.1089%2Fhum.1997.8.17-2019&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1043-0342&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1043-0342&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1043-0342&client=summon |